La vendita allo scoperto per ABM Indus dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ABM Indus. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ABM Indus (NYSE:ABM) Azioni, Report sulle vendite allo scoperto

ABM Indus

ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AVGO

SWBI

Azioni in movimento nel pre-market del 6 settembre 2024: ecco i titoli chiave che gli investitori devono tenere d&#39;occhio oggi.

Pre-market: 5 titoli da monitorare oggi, 6 settembre 2024

ABM Industries Inc

ALBIOMA by Albioma

ABCOURT MINES INC B by Abcourt Mines Inc.

Abcourt Mines Inc

AMER BIO MEDICA CORP by American Bio Medica Corp.

American Bio Medica Corp

American Battery Technology Co

ABN AMRO Bank NV

ADVANCED BIOMEDICAL TECHS by Advanced BioMedical Technologies, Inc.

Advanced BioMedical Technologies Inc

<a href="https://www.globenewswire.com/Tracker?data=u__EcdHyxyoNqn01p2yG1vMlvN47sF2FkFGe-sdX9GqR7I8HbDcDvEmZIPlZ_Yn7tZ_u1HkDpxUgsHgDNw1rAA==">ABM (NYSE:</a><a href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>), a leading provider of integrated facility services, infrastructure solutions, and parking management, today announced a distributorship agreement with <a href="https://www.globenewswire.com/Tracker?data=6xDlfYiK6RHtxZ1B-aj2ncXx1sxHNVHZ23D8Jn-FH-DacqXwzc2NmQpLGqLUrmu579-M9-ewGQne0QCgid1glNP6MsNZVVW4WVYDCHLE154=">Samsung C&amp;T</a> Charging Solutions, making ABM an authorized distributor and servicer of EVSIS-branded DC Fast Chargers. Samsung C&amp;T Charging Solutions is an equity partner of the Korean DC Fast Chargers manufacturer EVSIS, which is entering the United States market. &nbsp;
The EVSIS chargers are versatile and high-quality, with best-in-class technology that integrates seamlessly with the cloud-based <a href="https://www.globenewswire.com/Tracker?data=3c82g6zuJHtSlAHprFkNAjBjCYt4m5ugaDVEOVcjLBVGGtXdtXbKN6PSQ4TiIUyBdFMVw9x56CoPQqtRjRUAKqPsYPA9-GcgvqBAg1U9nPthwR9LjjsCsSJBg959koScU7oe-2KGY5oqZMnC1Uz5TYgdBXupjsqJNA735KYBiZHgs8yPctcL0MeitK3PEKsTO_vCxScGVvr1Q1PFuoaF0iHFUJwUjGX3u_EkgihogBxHnqjEywISQD2bnXgqzSvz0G3rT_IQdZUhMe-GA8Ce17UE5ttef9FVGvhiodgkpUBff-2OOtbhOEl9ceGNmMo58EaHEBBQRmerk_yLD9fSjFZ4pxTvB5AKdTBcbqz7MZZnMHMRNIQ43EmEh1eYKI0Isdp8A7k_IJiSU_BJGBCiI_t_0TfM6S1_X2aNHctrDOgro76lkXPT31tsJY1C4kjqG2R8UT3NtxMlke190kGPGFCP5DcqAA6RndYJmFzjAoeAN2Cb11pcq_PBpDJpKjiEJzwayugvIqKALSnJmxxGt3VlHs1HPC1kDc-n022mlpPz22CAKJypZIMvWFI_1Mg6sgrmgDrlzLjwAmk7AxQO1h5QZtK3pFGCJ4Hu_3AMtDyQDttkFPb7m3dy1l_Mr6mFxCVjq8ipJQcT7FGm4N_v84nC7WOreAwkazTulVdnMAgZLoPUqHwqp0ZyuMTfJG8DPGkIP2KVT6AI2OnUXnq6K0q5n-0NKitWaXP0_GmHnBREYeuE19LbJTfVKELSl1xz_4LXljkXpixEzPGnFAMjAJK4KmW2HMKpC5qZba28AO6004-TyTVx8QQMsXfEDPWIUXlzjfmsdmmuKb-wwB4_jZPUAMSQhECTNd6JAhZpHWW8ZRhQ7uyn_rft56grwjI-2jCXDWfItZ-DFdsu6dh6risAwVOVDF89u2GcC7jcIbxKZNlpVdmEmnq5Kca4hbSMwQGdBPM5jPbpIOb-28flmk2PVYoEPl2mz4Z4qnnM6AVppBeA8Xgx8LuzEGpOmHGBX1zeiy5lHdkQjGIIVAlbAW-AuFOmQjgEtwgRFbgnOGcgVmQdlcz1sYT-YjQnuP_qAQ2Nshrdbw9B3zyzDxenKk2vbnO-9Qqyx0VkdoW6ddwWkGPmOPlgmsQuzhs5wJ4a">ABM EV OS</a> platform – enabling for scalable expansion, intelligent monitoring, remote operation management, comprehensive reporting, and automatic infrastructure diagnostics. Through this partnership, all EVSIS chargers will be offered and serviced alongside ABM's current charger portfolio.

SSNLF

ABM Expands Charger Portfolio With Samsung C&T Charging Solutions Partnership

GE HealthCare Technologies&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gehc#NASDAQ">GEHC</a>) MIM Software recently announced the receipt of FDA clearance for performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification.
With MIMneuro, a vendor-neutral solution, this new Centiloid scale tool is likely to be able to assist physicians in more accurately determining the density of amyloid plaque in a patient&#39;s brain. Amyloid PET radiotracers help visualize amyloid plaque density in patients being evaluated for Alzheimer&#39;s disease.
<h2>Likely Trend of GEHC Stock Following the News</h2>
Following the announcement, shares of the company moved nearly 1.7% north to $88.53 at yesterday&#39;s close.
GE HealthCare is one of the leading providers of medical technology, pharmaceutical diagnostics, and digital solutions with a focus on precision care. In March, GE Healthcare acquired MIM Software, which added AI-based solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics and research organizations worldwide. Owing to the strong potential for the diagnostic imaging market, we expect the market sentiment to remain positive around this news.
Meanwhile, GEHC currently has a market capitalization of $39.63 billion. It has an earnings yield of 4.91% is much higher than the industry&#39;s yield of negative (7.12)%. In the last reported quarter, GEHC delivered an earnings surprise of 2.04%.
<h2>More on the GEHC&#39;s Centiloid Scaling Tool</h2>
A significant number of people in the United States develop dementia, with Alzheimer&#39;s disease accounting for 60-80% of dementia cases. The condition affects memory, thinking and behavior, and symptoms typically start with mild cognitive impairment and eventually grow severe enough to interfere with daily tasks. A characteristic feature of this condition is the build-up of beta-amyloid protein in the brain, which is connected to tissue loss and cell death.
In order to assist physicians in identifying potential patients for amyloid-targeting therapies, PET imaging makes it possible to visualize and quantify amyloid protein. A global consortium of physicians and scientists created the Centiloid scale with the goal of harmonizing quantitative amyloid imaging analysis throughout radiotracers and organizations.
GE HealthCare&#39;s MIM Software now offers MIMneuro with Centiloid scaling, leveraging an automated workflow to help guide users through generating and understanding the quantitative result. The software takes the PET amyloid images, provides clinicians instructions to automatically generate quantitative results, and presents the data in a standardized report for clinicians to review alongside the images. As a result, clinicians can more easily access the quantitative data they need to evaluate patients.
MIMneuro with Centiloid scaling is the latest addition to GE HealthCare&#39;s comprehensive suite of products and solutions, which span the Alzheimer&#39;s disease care pathway from diagnosis through treatment monitoring.
<h2>Favorable Industry Prospects for GEHC</h2>
Per a report by Future Market Insight, the global brain imaging and neuroimaging market was estimated to be $13.7 billion in 2023 and is anticipated to surpass $22.4 billion by 2033 at a CAGR of 5.1%. The brain imaging and neuroimaging market is primarily driven by the rising incidence and prevalence of neurological disorders, increased awareness of neurodegenerative diseases, an increase in traumatic brain injuries, and increased applications of brain imaging and neuroimaging in clinical trials.
Given the market potential, the latest FDA clearance of MIM Software&#39;s Centiloid Scaling Tool is likely to provide a boost to GEHC&#39;s business.
<h2>GEHC&#39;s Notable Developments</h2>
In August, GEHC announced the receipt of the CE mark for its Vscan Air SL wireless handheld ultrasound system with Caption AI. The company also received the CE mark for the use of ECG-less cardiac computed tomography scanning on its Revolution Apex platform.
The company also collaborated with the University of California San Diego School of Medicine. The tie-up aims to investigate advanced magnetic resonance imaging protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians.
<h2>GEHC&#39;s Price Performance</h2>
In the past six months, GEHC shares have lost 2.6% compared with the industry&#39;s decline of 12.4%. The S&amp;P 500 has gained 7.6% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/51/78442.jpg?v=1728486434" />
Image Source: Zacks Investment Research
<h2>GE HealthCare&#39;s Zacks Rank &amp; Stocks to Consider</h2>
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.
<a href="https://www.zacks.com/stock/news/2338704/gehc-stock-rises-as-fda-clears-mim-software-s-centiloid-tool?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2338704">To read this article on Zacks.com click here.</a>

Biotech

Earnings Beats

Large Cap

Mid Cap

Analyst Ratings

General

GEHC

GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool

Solventum Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/solv#NYSE">SOLV</a>) recently announced the launch of the V.A.C. Peel and Place Dressing, an integrated dressing and drape that can be applied quickly&nbsp;and worn by patients for up to seven days.
Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be changed at least three times a week.
The latest launch by SOLV is likely to solve the persisting issues of traditional dressings for negative pressure wound therapy, making it more accessible and less painful. The V.A.C. Peel and Place Dressing is an essential innovation in wound care that has the potential to improve outcomes, save both time and money and enhance the overall patient and clinician experience.
Due to the factors mentioned above, the product is likely to witness substantial demand in the field of negative pressure wound therapy and contribute to the top-line growth of the company, thus driving the share price of SOLV higher.
<h2>More on the SOLV&#39;s V.A.C Peel and Place Dressing</h2>
The latest development in V.A.C.&nbsp;Therapy is the new V.A.C.&nbsp;Peel and Place Dressing. Due to its integrated dressing and drape design, dressing application and changes are easier to perform, requiring less time and training. Moreover, it has an integrated non-adherent, perforated layer that reduces tissue ingrowth and lessens discomfort when removing the dressing.
The V.A.C. Peel and Place Dressing is suggested for use on wounds up to 6 cm deep, covering chronic, acute, traumatic, subacute, and dehisced wounds. Additionally, it can be used on partial thickness burns, pressure ulcers (such as those caused by diabetes), venous insufficiency, flaps, and grafts.
Research has demonstrated that the V.A.C. Peel and Place Dressing can substantially reduce&nbsp;therapy application time. It can also lower hospital bedside expenditures significantly&nbsp;because of fewer dressing changes and lower&nbsp;home nursing visits per week.
V.A.C.&nbsp;Therapy has been linked to noticeably faster wound healing. Over nearly three decades, it has been used globally to treat more than 10 million wounds. However, a rise in wound numbers is increasing due to aging populations and the incidence of chronic illnesses such as obesity and diabetes. The V.A.C. Peel and Place Dressing enables V.A.C. Therapy to be used on a wider range of patients across the continuum of care in both acute and post-acute settings.
The product is available now in the United States and Canada. Additional global regulatory submissions and approvals are pending.
<h2>Favorable Industry Prospects for SOLV</h2>
Per a report by Grand View Research, the global negative pressure wound therapy market size was estimated to be $2.5 billion in 2023 and is expected to witness a CAGR of 6.6% from 2024 to 2030.
Given the market potential, SOLV&#39;s V.A.C Peel and Place Dressing is likely to provide a boost to SOLV&#39;s business.
<h2>SOLV&#39;s&nbsp;Price Performance</h2>
In the past six months, SOLV shares have lost 1.1% compared with the industry&#39;s decline of 1.3%. The S&amp;P 500 has gained 6.4% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9f/77363.jpg?v=2024522534" />
Image Source: Zacks Investment Research
<h2>SOLV&#39;s Zacks Rank and Stocks to Consider</h2>
Currently, SOLV has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries presently carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.
<a href="https://www.zacks.com/stock/news/2334834/solventum-shares-may-gain-on-the-launch-of-its-new-v-a-c-therapy?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334834">To read this article on Zacks.com click here.</a>

Health Care

Events

SOLV

Solventum Shares May Gain on the Launch of Its New V.A.C Therapy

UBS analyst Joshua Chan maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Neutral and raises the price target from $51 to $55.

Price Target

UBS Maintains Neutral on ABM Indus, Raises Price Target to $55

Truist Securities analyst Jasper Bibb maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Hold and raises the price target from $49 to $55.

Truist Securities Maintains Hold on ABM Indus, Raises Price Target to $55

Baird analyst Andrew Wittmann maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Neutral and raises the price target from $49 to $56.

Baird Maintains Neutral on ABM Indus, Raises Price Target to $56

WIIM

ABM Industries shares are trading lower. The stock gained after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates but has since reversed.

ABM Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) shares are trading higher after the company reported&nbsp;third-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40746750/abm-reports-third-quarter-fiscal-2024-results-and-raises-outlook-for-fiscal-year-2024-adjusted-eps" rel="noreferrer noopener">earnings and raised&nbsp;guidance</a>.
Sales grew 3.3% Y/Y to $2.09 billion, beating the consensus of $2.037 billion. Revenue growth was driven by Technical Solutions (+25% Y/Y) and Aviation (+13%), with Education increasing by 4% Y/Y.
Operating expenses increased&nbsp;3.7%&nbsp;Y/Y to&nbsp;$1.83 billion, and operating profit declined&nbsp;73.1% Y/Y to&nbsp;$37.4 million in the quarter.
Adjusted EBITDA rose 2% Y/Y to $128.1 million, with the margin remaining flat Y/Y at 6.4%. Adjusted EPS of $0.94, up 19% Y/Y, beating <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">the consensus of $0.86</a>.
Operating cash flow for the quarter totaled&nbsp;$79.5 million, down from&nbsp;$149.1 million&nbsp;a year ago. As of July-end, ABM held cash and equivalents of&nbsp;$86.3 million.
Dividend:&nbsp;ABM declared a cash dividend of&nbsp;$0.225&nbsp;per common share, payable on November 4, 2024, to shareholders of record on October 3, 2024.
Scott Salmirs, President &amp; Chief Executive Officer, said, &#8220;Our investments in the energy resiliency markets, particularly in microgrids, which grew significantly, as well as those investments in technology, including tools that improve labor efficiency and our go-to-market approach, helped us deliver another quarter of solid organic growth on an enterprise level and resilient margins.&#8221;&nbsp;
&#8220;This performance was supported by our focus on market segmentation, especially our purposeful weighting towards higher performing Class A properties, which enabled us to once again perform well in our Business &amp; Industry segment, despite a still choppy commercial real estate environment.&#8221;
2024&nbsp;Outlook: ABM raised the adjusted EPS outlook to&nbsp;$3.48 &#8211; $3.55 (from $3.40 &#8211; $3.50)<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> versus the&nbsp;$3.47&nbsp;consensus</a>.
Price Action: ABM shares are up 6.95%&nbsp;at&nbsp;$60.00 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40746080/us-stocks-set-for-steep-fall-amid-heightened-anxiety-ahead-jobs-data-vix-surges-strategist-flags-2-" target="_blank" rel="noreferrer noopener">US Stocks Set For Steep Fall Amid Heightened Anxiety Ahead Jobs Data, VIX Surges: Strategist Flags 2 Reasons Why He Expects More Volatility Ahead</a></li>
</ul>

Equities

Guidance

Movers

ABM Industries Delivers Solid Q3 Results On Investment In Energy Market, Boosts Guidance

ABM Industries shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

ABM Raises FY24 Adjusted EPS Outlook To $3.48-$3.55 (From $3.40-$3.50 ) Vs. $3.47 Est.

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.86 by 9.3 percent. The company reported quarterly sales of $2.094 billion which beat the analyst consensus estimate of $2.037 billion by 2.81 percent. This is a 3.25 percent increase over sales of $2.028 billion the same period last year.

ABM Indus Q3 2024 Adj. EPS $0.94 Beats $0.86 Estimate, Sales $2.094B Beat $2.037B Estimate

The <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40718185/could-august-jobs-numbers-keep-recession-fears-at-bay-this-time-is-different-analys">non-farm payrolls data is keeping traders on the tenterhook</a> and the index futures point to a negative opening on Friday. The caveat here is the the market mood could quickly pivot to positivity if the job gain comes in line with expectations. Following the data, traders get to hear from two Federal Reserve officials, possibly the last ones ahead of the Sept. 17-18 Federal Open Market Committee Meeting, given the blackout period starts on Saturday. 
The market direction depends on which worries the traders the most &#8211; a slowdown or the rate trajectory. If the job gains grossly disappoint just as its ADP counterpart did, the odds of a 50 basis-point could be in play. But it remains to be seen whether a weak job market would be considered a reason good enough to liquidate risky bets. The CBOE Volatility Index, commonly called the VIX, spiked by over 13%.
On the corporate front, Broadcom Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) soft guidance is weighing down on the chipmaker&#8217;s stock and that of its peers as well. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.12%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.63%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.33%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) plunged 0.61% to $546.24 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slumped 1.05% to $456.21, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks went about in a listless manner on Thursday as traders digested a weak ADP private payrolls number, fairly in-line initial jobless claims data and better-than-expected service sector activity readings. After a negative open, the major indices recovered and rose in the morning session. Lingering worries about Friday&#8217;s payroll numbers dragged the market lower yet again and the indices began to move in a lackluster manner before closing mixed. 
Gains in some heavy-weighted tech stocks lifted the Nasdaq to a higher close, as it snapped a two-session losing streak, while the S&amp;P 500 Index finished with a modest loss. The 30-stock Dow Jones Industrial Average and the small-cap Russell 2,000 Index settled moderately lower.
Eight of the 11 S&amp;P 500 sectors finished in the red, with industrial, material healthcare and financial stocks seeing marked weakness. On the other hand, consumer discretionary, communication services and IT stocks found some buying interest.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.25%</td>
<td>17,127.66</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-0.30%</td>
<td>5,503.41</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>-0.54%</td>
<td>40,755.75</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.61%</td>
<td>2,132.05</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
After August proved to be a wild month for stocks, September has so far lived up to expectations of being a seasonally weak month, and an analyst cautioned that the near term does not hold out much promise. LPL Financial Chief Technical Strategist Adam Turnquist said the S&amp;P 500&#8217;s recovery has stalled just under its record highs hit in mid-July. 
The index stalled just around its 20- and 50-day simple moving averages. Turnquist noted that there is a price gap at 5,455 and further down, it has support around its August low of 5,119. In the event of a rally August and July highs of 5,648 and 5,667, respectively, will serve as resistances, he added.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06044452/image-1-11-1024x536.png" alt="" class="wp-image-533772" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06044452/image-1-11-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06044452/image-1-11-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06044452/image-1-11-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06044452/image-1-11.png 1461w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Source: TradingView
&#8220;Momentum indicators have turned bearish, and signs of defensive leadership have begun to emerge, pointing to more volatility ahead,&#8221; Turnquist said, adding that &#8220;breakdowns in longer-duration Treasury yields, crude oil, and copper, along with a simultaneous breakout in gold, provide a warning sign of rising risks to an economic soft landing.&#8221;
Upcoming Economic Data:
<ul>
<li>The August non-farm payrolls report, due to be released by the Bureau of Labor Statistics at 8:30 a.m. EDT, is widely expected to show that 161,000 jobs were added during the month, an increase from 114,000 jobs added in July. The jobless rate is expected to tick down from 4.2% to 4.3%. The average hourly wages, an inflation measure, may have increased by 3.7%, slightly up from the 3.6% growth in July.</li>
<li>New York Fed President John Williams is due to speak at 8:45 a.m. EDT and Fed Governor Christopher Waller at 11 a.m. EDT. </li>
</ul>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Stocks In Focus:
<ul>
<li>Broadcom fell about 8%<a href="https://www.benzinga.com/premarket"> in premarket trading</a> as traders reacted negatively to the chipmaker&#8217;s fourth-quarter revenue guidance. </li>
<li>Other stocks moving on earnings are Smartsheet Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) (up about 4%), Smith &amp; Wesson Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) (down over 7%), UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) (over 9%) and Zumiez Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) (up over 4%).</li>
<li>ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) and Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) are among the companies reporting <a href="https://www.benzinga.com/earnings">quarterly results ahead of the market opening.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures moved sideways under the $70 level and gold futures are modestly higher, approaching the $2,550 level, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded below $56K level and were lower. The 10-year Treasury note yield slid 3.4 points to 3.699%. 
Most Asian markets fell sharply ahead of the U.S. jobs data, while Hong Kong did not trade due to Super Typhoon Yagi threat. European stocks also pulled back sharply in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40724455/peter-schiff-says-illusion-of-a-strong-labor-market-fading-faster-than-kamala-harris-post-convention">Peter Schiff Says &#8216;Illusion Of A Strong Labor Market&#8217; Fading Faster Than Kamala Harris&#8217; Post-Convention Popularity Spike As Job Openings Slide To Lowest In 3.5 Years</a></li>
</ul>

Futures

Previews

Economics

Federal Reserve

Tech

$BTC

PATH

SMAR

ZUMZ

US Stocks Set For Steep Fall Amid Heightened Anxiety Ahead Jobs Data, VIX Surges: Strategist Flags 2 Reasons Why He Expects More Volatility Ahead

ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/ABM/earnings">opening bell on Friday, Sept. 6.</a>
Analysts expect the New York-based company to report quarterly earnings at 86 cents per share, up from 79 cents per share in the year-ago period. ABM is projected to post revenue of $2.04 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
On June 24, ABM said it has acquired Quality Uptime Services, Inc, a prominent player in the critical power services industry for an all-cash purchase price of $119 million..
ABM shares gained 0.2% to close at $56.10 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c1499cb85e93000132aab8/andrew-wittmann">Baird analyst Andrew Wittmann</a> maintained a Neutral rating and raised the price target from $48 to $49 on June 10. This analyst has an accuracy rate of 78%.</li>
<li>UBS analyst Joshua Chan maintained a Neutral rating and boosted the price target from $45 to $51 on June 7. This analyst has an accuracy rate of 74%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/65522755a54dc20001b245f7/jasper-bibb">Truist Securities analyst Jasper Bibb </a>maintained a Hold rating and cut the price target from $53 to $45 on March 8. This analyst has an accuracy rate of 68%.</li>
<li>Keybanc analyst Sean Eastman maintained an Overweight rating and slashed the price target from $51 to $48 on Sept. 11, 2023. This analyst has an accuracy rate of 86%.</li>
<li>Deutsche Bank analyst Faiza Alwy downgraded the stock from Buy to Hold and cut the price target from $65 to $43 on Sept. 8, 2023. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying ABM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06003539/image-42-1024x505.png" alt="" class="wp-image-533405" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06003539/image-42-1024x505.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06003539/image-42-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06003539/image-42-768x379.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06003539/image-42.png 1352w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

ABM Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Dow Jones index falling more than 200 points during the session. The S&amp;P 500, meanwhile, recorded losses for a third session in a row.
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 4.9% on Thursday after the company announced plans to roll out its full self-driving (FSD) driver assistance software in Europe and China in the first quarter of 2025. Shares of G-III Apparel Group, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) jumped 22% during Thursday&#8217;s session after the company reported better-than-expected second-quarter adjusted EPS results and issued its FY25 guidance above estimates.
On the economic data front, U.S. private businesses added 99,000 workers to their payrolls in August compared to a revised 111,000 gain in July and versus market estimates of 145,000. U.S. initial jobless claims fell by 5,000 from the prior week to 227,000 in the week ending August 31, compared to market estimates of 230,000.
Most sectors on the S&amp;P 500 closed on a negative note, with healthcare, industrials, and financials stocks recording the biggest losses on Thursday. However, communication services and consumer discretionary stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 219 points to 40,755.75 on Thursday. The S&amp;P 500 fell 0.30% to 5,503.41, while the Nasdaq Composite gained 0.25% at 17,127.66 during Thursday's session.
Investors are awaiting earnings results from ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>), The Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>), and Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 46.8, the index remained in the &#8220;Neutral&#8221; zone on Thursday, versus a prior reading of 49.7.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:<a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

GIII

TSLA

Dow Dips Over 200 Points, S&P Falls For 3rd Session In A Row: Fear & Greed Index Remains In 'Neutral' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) to report quarterly earnings at 86 cents per share on revenue of $2.04 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. ABM shares gained 3.4% to $58.00 in after-hours trading.</li>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) <a href="https://www.benzinga.com/news/earnings/24/09/40741225/broadcom-q3-earnings-revenue-beat-eps-beat-continued-strength-in-ai-solutions-and-vmware-2024-ai-gu">reported</a> better-than-expected third-quarter financial results after the closing bell on Thursday. The company said it expects fourth-quarter revenue of approximately $14 billion. Broadcom shares fell 6.7% to $142.53 in the after-hours trading session.</li>
<li>Analysts are expecting Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) to post quarterly earnings at $3.46 per share on revenue of $1.04 billion. The company will release earnings before the markets open. Big Lots shares rose 23% to $0.5602 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) reported worse-than-expected first-quarter financial results on Thursday. The company reported quarterly sales of $88.334 million which missed the analyst consensus estimate of $102.525 million. Smith &amp; Wesson Brands shares declined 7.3% to $13.15 in the after-hours trading session.</li>
<li>Analysts expect Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) to report quarterly earnings at $1.20 per share on revenue of $12.96 billion after the closing bell. Brady shares gained 4.2% to $74.83 in the after-hours trading session.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>
Photo courtesy: Shutterstock

Broadcom, ABM Industries And 3 Stocks To Watch Heading Into Friday

PROCEPT BioRobotics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prct#NASDAQ">PRCT</a>) recently announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. This clearance marks an important achievement for PROCEPT BioRobotics as Aquablation therapy continues its rapid adoption, with more than 400 robotic systems now installed across the United States.
HYDROS Robotic System presents major technological innovations intended for broad market adoption after years of research and development, which the company expects to drive the next stage of its growth.
<h2>More on the HYDROS Robotic System</h2>
Aquablation therapy is&nbsp;a minimally invasive surgical procedure that uses a computer-controlled waterjet to remove prostate tissue, which causes lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy, combining cutting-edge technology with user-friendly features designed to deliver better clinical outcomes for patients and healthcare providers.
HYDROS features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is intended to increase productivity, elevate the experience of surgeons and personnel, and provide a more precise and consistent treatment plan for superior clinical results.
HYDROS is likely to move to full market release within the current quarter and be available immediately to hospitals across the United States.
<h2>Key Features of the HYDROS Robotic System</h2>
HYDROS System features FirstAssist AI, which uses advanced image recognition software to precisely detect important anatomy on ultrasound and recommend the best course of action for each patient. It was developed using a library of actual Aquablation therapy treatments.
The system combines digital cystoscopy, next-generation ultrasound imaging, and two high-definition touchscreens to provide simultaneous viewing of ultrasound and cystoscopy pictures and improved anatomy visualization.
The robot executes the surgeon&#39;s treatment plan to remove obstructive tissue while safeguarding vital anatomical structures using a heat-free waterjet. This enables efficient and predictable waterjet execution, standardizing the operative experience across a wide range of prostate sizes and shapes.
<h2>Industry Prospects</h2>
Per a report by Grand View Research, the global BPH treatment devices market, valued at $1.42 billion in 2022, is projected to witness a CAGR of 8.9% from 2023 to 2030.
Technological improvements, increased prevalence of urological illnesses, and growing patient awareness of potential treatment options have all contributed to the expansion of the BPH treatment device market.
The need for BPH treatment devices is also expected to rise soon due to the growing demand for innovative, minimally invasive, non-invasive technologies and Aquablation treatments, which have fewer side effects and quicker recovery times than open surgical techniques.
<h2>Price Performance</h2>
For the year-to-date period, PRCT&#39;s shares have gained 99% compared with the industry&#39;s rise of 9.4%. The S&amp;P 500 increased 17.8% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/62/75041.jpg?v=401489730" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Stocks to Consider</h2>
PRCT carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2325937/procept-biorobotics-prct-hydros-system-gets-fda-clearance?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325937">To read this article on Zacks.com click here.</a>

PRCT

PROCEPT BioRobotics' HYDROS System Gets FDA Clearance

CollPlant Biotechnologies&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clgn#NASDAQ">CLGN</a>) and Stratasys Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssys#NASDAQ">SSYS</a>) recently announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer.
The study is likely to focus on the ability of implants to grow natural breast tissue and completely degrade over time. As part of the study, 3D printed breast implants consisting of 200cc in the volume of CollPlant&#39;s rhCollagen-based bioinks produced on a Stratasys&#39; Origin printer are to be tested. The pre-clinical study marks a significant step forward in the companies&#39; combined effort to provide patients with care using regenerative medicine instead of traditional implants.
<h3>More on the News</h3>
While CollPlant is a cutting-edge firm in regenerative and aesthetic medicine, creating innovative technologies and products based on its rhCollagen for tissue regeneration and organ production, Stratasys is a leader in polymer 3D printing solutions. Stratasys modified the Origin printer to print the regenerative implants after the two companies announced a collaboration in April 2023. CollPlant is expecting to have initial results from the study in the first half of 2025.
The collaboration between CollPlant and Stratasys is currently focused on developing a bioprinting solution for CollPlant&#39;s breast implants as well as ways to expedite the implant&#39;s construction process. The goal of the study is to evaluate the implants&#39; capacity to stimulate the formation of native breast tissue and eventually degrade entirely.
A substantial share of the total addressable breast implant market is likely to be captured by CollPlant&#39;s innovative breast implants, which are designed to regenerate an individual&#39;s natural breast tissue without triggering an immune reaction. These implants could offer a ground-breaking substitute for reconstructive and cosmetic procedures.
<h3>Industry Prospects</h3>
Per a report by The Brainy Insights, the global breast implant market is estimated to be $3 billion, while breast reconstruction and augmentation procedures represent the second most common plastic surgery procedure performed worldwide.
The most common breast augmentation or reconstruction procedures utilize synthetic breast implantations made of silicone, an artificial substitution for natural regenerated tissue with a risk of complications.
<h3>Price Performance</h3>
For the year-to-date period, CLGN&#39;s shares have lost 24.1% against the industry&#39;s rise of 0.2%. The S&amp;P 500 increased 17.7% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1d/74826.jpg?v=1569553057" />
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Stocks to Consider</h3>
CLGN carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), ABM Industries carries a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2325247/collplant-clgn-stratasys-initiate-study-for-breast-implants?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325247">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

CLGN

SSYS

CollPlant, Stratasys Initiate Study for Breast Implants

McKesson&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>) is witnessing strong momentum, with its shares having rallied 18.3% year to date compared with 0.6% growth of the&nbsp;industry. The S&amp;P 500 Composite has risen 16.5% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments &mdash; Distribution Solutions and Technology Solutions. The first segment distributes branded and generic pharmaceutical drugs, along with other healthcare-related products, on a global basis. It also provides practice management, technology, clinical support and business solutions. The second segment offers enterprise-wide clinical, patient care, financial, supply chain and strategic management software solutions.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/41/74620.jpg?v=129418765" />
Image Source: Zacks Investment Research
<h3>Catalysts Driving Growth</h3>
The rally in MCK&#39;s shares can be attributed to the strength of its robust U.S. Pharmaceutical business. This optimism, led by a solid first-quarter performance and increasing demand for healthcare, is expected to contribute further.
Investors seem to be optimistic regarding the updated earnings guidance. On first-quarter 2025 earnings call, McKesson raised its adjusted earnings per share guidance for fiscal 2025. It now expects adjusted EPS in the range of $31.75-$32.55 (previously $31.25-$32.05), which represents growth of 16-19% from the prior-year level. Revenues are expected to grow 15-17% from the prior-year figure.
The company recorded a significant uptick in its overall top line during the first quarter. This growth was primarily driven by the U.S. Pharmaceutical segment, which saw increased prescription volumes, including higher volumes from specialty products, retail national account customers and GLP-1 medications.
As a result of the major market disruption caused by COVID-19 during the past three years, McKesson has benefited from improved demand across numerous verticals within the medical sector, particularly surgeries. A rebound in demand-driven volumes is also being observed by the company. Sales are also being positively impacted by increasing product pricing.
In April, McKesson launched Project Oasis, an initiative aimed at advancing health equity for at-risk populations in underserved communities. The rising demand for extended and primary care is expected to drive the top line of the Medical-Surgical business in fiscal 2025.
However, a weak first-quarter Medical-Surgical business due to challenges in the primary care channel raises concerns. Although the company has started boosting its operational efficiency and increasing its cost optimization efforts, it will likely take a while to get reflected in the company&#39;s performance.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<h3>Stocks to Consider</h3>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2323842/mckesson-mck-stock-gains-18-ytd-what-s-driving-the-rally?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2323842">To read this article on Zacks.com click here.</a>

McKesson Stock Gains 18% YTD: What's Driving the Rally?

ABM Awarded NASPO ValuePoint Contract To Provide EV Charging Infrastructure Solutions To State, Local Government, And Educational Entities Nationwide

Bio-Rad&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>) business performance has been affected by Biopharma&#39;s softness, macroeconomic conditions in China and competitive pressure. The stock carries a Zacks Rank #4 (Sell).
Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has been experiencing. Management puts forth that BioPharma&#39;s softness has resulted in the Life Science Segment&#39;s growth at a slower pace.
In the second quarter of 2024, negative BioPharma macro trends persisted. Bio-Rad experienced reduced demand from biopharma customers for its process chromatography resins and from both biopharma and smaller biotech customers for Life Science research products, reflecting the ongoing destocking trend across the industry. Bio-Rad experienced weaker second-quarter sales in Asia as China is currently entangled in a challenging research funding environment and Japan too is facing constrained funding issues. Additionally, the Korean government&#39;s spending on life science research remained soft throughout the second quarter as part of the deficit reduction.
In recent times, Bio-Rad&#39;s margin performance has been affected by elevated raw material costs, increased logistics costs and higher employee-related expenses. In the second quarter, the company&#39;s gross margin was additionally impacted by an unfavorable product mix, with a higher-than-anticipated percentage of instrument sales versus reagents, as well as lower-than-projected revenues in the Life Science Group.
<div class="chart_embed">
<h3>Bio-Rad Laboratories, Inc. Price</h3>
<img alt="Bio-Rad Laboratories, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/36/1723467995.png" style="height:251px; width:545px" title="" />
Bio-Rad Laboratories, Inc. price | Bio-Rad Laboratories, Inc. Quote
These macroeconomic factors, particularly the ongoing labor unrest, rising wages and raw material costs, along with ongoing geopolitical unrest, are resulting in a significant escalation in the company&#39;s operating expenses. Bio-Rad posted a 27.8% year-over-year decline in operating profit in the second quarter. Based on all these factors, Bio-Rad lowered its adjusted operating margin projection for 2024 to 12-13% (down from the earlier guidance of 13.5-14%). For 2024, our model projects a 10.6% decline in the company&#39;s GAAP operating profit on a 3.7% rise in expenses.&nbsp;
</div>
Meanwhile, Bio-Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit Bio-Rad&#39;s ability to switch to strategies like price increases and other drivers of cost increases. Further, the extension of the public tender commitments to multiple years by the government, resulting in a reduced number of annual tenders, has led to aggressive tender pricing by Bio-Rad&#39;s competitors. Thus, Bio-Rad faces pricing pressure resulting from increased competition, which makes it difficult for the company to manage its operational, financial and business conditions efficiently.
On a positive note, Bio-Rad is consistently developing its foothold in the rapidly growing digital PCR space to address additional opportunities in the PCR market. The pipeline of Bio-Rad&#39;s QX600 Droplet Digital PCR (ddPCR) platform is currently robust and growing. Backed by the tremendous customer response, the company continues to ramp up production capacity to accommodate the ongoing demand.
In the second quarter, despite the Droplet Digital PCR franchise being soft, ddPCR reagents and consumables grew low in single digits. The newly launched ddPCR assay is successfully gaining share in the oncology and cell and gene therapy markets. Considering all these factors, the company is optimistic about ddPCR&#39;s growth in the coming quarters.
Sales of the clinical diagnostics group in the second quarter increased 2.1% on a reported basis and 3.2% on a currency-neutral basis. Growth of the clinical diagnostics group was primarily backed by increased demand for quality controls and blood typing products on a geographic basis. Currency-neutral year-over-year revenues in the diagnostics group posted balanced growth across all regions of the company. The company continues to invest in supporting the growth of this segment while building a position in new molecular diagnostics segments.
<h3>Key Picks</h3>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each.
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2320781/bio-rad-bio-faces-low-biopharma-demand-competitive-pressure?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2320781">To read this article on Zacks.com click here.</a>

Bio-Rad Faces Low BioPharma Demand, Competitive Pressure

ABM Industries, Inc. (ABM) Q3 2024 Earnings Call Transcript

Truist Financial analyst Jasper Bibb assigned a Hold rating to the stock today. The company's shares closed last Friday at $51.29. Bibb covers the ...

ABM Industries (ABM) Gets a Hold from Truist Financial

Maxim Group analyst Tate Sullivan has maintained their neutral stance on ABM stock, giving a Hold rating yesterday. Tate Sullivan has given his Hol...

Hold Rating on ABM Industries Amid Solid Performance but Limited Growth Prospects

Casella Waste Systems Dives On Its Big Capital Raise (Rating Upgrade)

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

ABM Industries: The Recent Pullback Could Be A Good Entry Point For A Long Position

ABM Industries: Sailing Secular Tailwinds With Its Resilient, Capital-Lite Ship

Middle Coast Investing Q3 2024 Investor Letter: Transitions And Timing

Undervalued Dividend Kings: October 2024

Truist Financial analyst Jasper Bibb assigned a Hold rating to the stock today. The company's shares closed yesterday at $52.00. According to TipRa...

Truist Financial Issues a Hold Rating on ABM Industries (ABM)

AAPL

ABBV

ACLS

AMZN

APOG

ATKR

ATRO

ATROB

BKNG

BOOM

BPOP

CADE

CBSH

CFFI

CHCO

CHRW

CINF

CMCSA

CSCO

CTBI

CUBE

CWST

DALN

ERIE

FCNCA

FCNCB

FCNCO

FCNCP

FFIN

FISI

FMAO

FULT

FUNC

GAERF

GAIN

GOGO

HBNC

HLNE

HWBK

INDB

INGR

KRUS

LANC

LRCX

LULU

MBIN

MNESP

MORN

MSEX

MSEXP

NDSN

OMAB

PTLO

RGLD

SCHW

SCVL

SFBS

SFNC

SPGI

SPTN

SRCL

SYBT

THFF

TROLB

UBSI

UMBF

UTMD

VICI

VMEO

WASH

WSBC

Press Releases

ABM Announces Partnership with Phoenix's Three Airports

Bryan Herta Autosport Partners with ABM to Showcase EV Capabilities at Pikes Peak International Hill Climb

ABM Expands Position and Capabilities in Fast-Growing Data Center Industry with Acquisition of Quality Uptime Services

ABM Among 60 Best Companies to Sell For

ABM Awarded NASPO ValuePoint® Contract for EV Charging Infrastructure Solutions

ABM to Announce Third Quarter 2024 Financial Results

ABM Reports Third Quarter Fiscal 2024 Results and Raises Outlook for Fiscal Year 2024 Adjusted EPS

Contracts

ABM Expands Charger Portfolio with Samsung C&T Charging Solutions Partnership

UGI Corporation Appoints Melanie Ruiz and David Bingenheimer to its Board of Directors

Comments

ABM Indus

Vendite allo scoperto

ABM Indus (NYSE:ABM) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO